Every Form 4 that AYTU BioPharma, Inc. (AYTU) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AYTU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AYTU filings page.
Disbrow Joshua R. reported acquisition or exercise transactions in this Form 4 filing.
Joshua R. Disbrow, chief executive officer and director of Aytu Biopharma, received a grant of 30,000 shares of restricted common stock on July 28, 2026 at $0.00 per share. One-third vests on July 28, 2027, with the rest vesting in eight equal quarterly installments beginning October 28, 2027. After this award, he directly holds 237,203 common shares.
PYSZCZYMUKA GREG reported acquisition or exercise transactions in this Form 4 filing.
Aytu BioPharma Chief Commercial Officer Greg Pyszczymuka received a grant of 20,000 shares of restricted common stock on July 28, 2026 at $0.0000 per share. One-third vests on July 28, 2027, with the remainder in eight quarterly installments from October 28, 2027. Following this award he directly holds 56,102 shares.
Disbrow Jarrett reported acquisition or exercise transactions in this Form 4 filing.
Jarrett Disbrow, Chief Business Officer of AYTU Biopharma, reported a grant of 15,000 shares of common stock as restricted stock. The award increases his direct holdings to 76,568 shares and vests over time starting July 28, 2027 in quarterly installments.
AYTU BioPharma’s Chief Financial Officer, Ryan J. Selhorn, received a grant of 25,000 shares of restricted common stock on July 28, 2026. One-third vests on July 28, 2027, with the remaining shares vesting in eight equal quarterly installments beginning October 28, 2027. Following this award, he directly holds 74,743 shares of common stock. The award is a grant/award acquisition rather than a market purchase and was not made under a Rule 10b5-1 trading plan.
LIU VIVIAN H reported acquisition or exercise transactions in this Form 4 filing.
Aytu Biopharma director Vivian H. Liu received a grant of 10,000 shares of restricted common stock on July 28, 2026. The restricted stock vests on July 28, 2027. Following this grant, Liu directly holds 29,825 shares of Aytu Biopharma common stock.
JAIN ABHINAV reported acquisition or exercise transactions in this Form 4 filing.
AYTU Biopharma reported that director Abhinav Jain received a grant of 10,000 shares of Common Stock as restricted stock on July 28, 2026, at a stated price of $0.0000 per share. These shares vest on July 28, 2027. After this award, Jain directly holds 29,500 shares of AYTU common stock.
DOCKERY CARL reported acquisition or exercise transactions in this Form 4 filing.
Aytu BioPharma director Carl Dockery received a grant of 10,000 shares of restricted common stock on July 28, 2026. The shares vest on July 28, 2027, and his directly held position increased to 31,152 shares after this compensation-related award.
Donofrio John Jr. reported acquisition or exercise transactions in this Form 4 filing.
Aytu BioPharma, Inc. director John Donofrio Jr. received a grant of 10,000 shares of restricted common stock on July 28, 2026. The award vests on July 28, 2027 and was priced at $0.00 per share, bringing his direct holdings to 23,762 shares.